Should You Buy Axsome Therapeutics Stock Before Feb. 23?

Axsome Therapeutics (NASDAQ: AXSM) has been a red-hot banal to ain implicit the past 12 months. During that stretch, it has soared by astir 75%, dwarfing the show of the S&P 500, which is up by 15% implicit that aforesaid clip frame. The healthcare company, which develops therapies for the cardinal tense system, has been generating beardown results successful caller quarters, giving investors plentifulness of reasons to beryllium bullish connected its future.

Its adjacent circular of results travel retired connected Feb. 23, erstwhile Axsome volition study its quarterly numbers for the past 3 months of 2025, and erstwhile it'll besides merchandise its full-year numbers. Should you bargain the banal earlier then?

Where to put $1,000 close now? Our expert squad conscionable revealed what they judge are the 10 champion stocks to bargain close now, erstwhile you articulation Stock Advisor. See the stocks »

When Axsome posted its astir caller net numbers successful November, the institution demonstrated immoderate awesome maturation with its gross rising by 63% connected a year-over-year basis, totaling $171 cardinal (for the play ended Sept. 30, 2025). It besides trimmed its nett nonaccomplishment from $64.6 cardinal successful the prior-year play to $47.2 million. Overall, it was an encouraging 4th for the company, which seemed to suggest it was progressing good and going successful the close direction.

Despite the coagulated net numbers, the banal didn't surge successful worth aft they came out. And adjacent a week later, the banal was up little than 2%. A overmuch bigger catalyst for the banal came astatine the extremity of the year, connected Dec. 31, 2025, erstwhile regulators granted precedence reappraisal for the exertion of the company's Alzheimer's drug, AXS-05. The people enactment day is acceptable for April 30 of this year. The time the quality came out, shares of Axsome jumped by 23%.

Axsome's banal has been connected an awesome tally implicit the past 12 months, pushing its marketplace capitalization up to astir $9.4 cardinal successful the process. The concern isn't profitable, however, and portion it has been growing, determination whitethorn inactive beryllium concerns astir conscionable however viable and harmless the institution is to put in. Meanwhile, it trades astatine a price-to-sales aggregate of 16, which isn't cheap.

For a institution that's inactive successful specified aboriginal maturation stages, it's apt to beryllium quality from regulators that has much of an interaction connected its stock terms than net results. As is evident with the crisp question successful terms astatine the extremity of past year, investors whitethorn beryllium eagerly anticipating support of AXS-05 much than thing else.